LM103

BIOLOGICAL4 trials

Sponsors

Suzhou BlueHorse Therapeutics Co., Ltd.

Conditions

Solid CancerSolid Tumor

Early Phase 1

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

RecruitingNCT05941936

Suzhou BlueHorse Therapeutics Co., Ltd.Solid Tumor

Start: 2023-05-19End: 2026-02-28Target: 5Updated: 2023-07-12

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Not yet recruitingNCT05971576

Suzhou BlueHorse Therapeutics Co., Ltd.Solid Tumor

Start: 2023-08-31End: 2026-08-31Target: 20Updated: 2023-08-02

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

Not yet recruitingNCT05971589

Suzhou BlueHorse Therapeutics Co., Ltd.Solid Tumor

Start: 2023-08-31End: 2026-08-31Target: 5Updated: 2023-08-02

An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours

RecruitingNCT06697665

Suzhou BlueHorse Therapeutics Co., Ltd.Solid Cancer

Start: 2024-01-23End: 2027-06-30Target: 10Updated: 2024-11-20

Related Papers

Multiple autologous tumor-infiltrating lymphocyte (LM103 infusion) therapy combined with immune checkpoint inhibitor induces repeated tumor regression in a patient with aggressive mucosal melanoma: a case report and literature review

Frontiers in Oncology2026-04-23